SCNI: Scinai Immunotherapeutics Ltd Financial Statements
Balance sheet, income statement, and cash flow statements for Scinai Immunotherapeutics Ltd (SCNI).
$2.85M Market Cap.
SCNI Market Cap. (MRY)
SCNI Shares Outstanding (MRY)
SCNI Assets (MRY)
Total Assets
$13.45M
Total Liabilities
$3.47M
Total Investments
$0
SCNI Income (MRY)
Revenue
$658.00K
Net Income
-$4.80M
Operating Expense
$8.06M
SCNI Cash Flow (MRY)
CF Operations
-$6.33M
CF Investing
-$12.00K
CF Financing
$3.44M
SCNI Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total Assets | $13,448,000 (-23.03%) | $17,472,000 (-35.45%) | $27,067,000 (-15.51%) | $32,036,000 (99.44%) |
Assets Current | $2,391,000 (-56.10%) | $5,447,000 (-62.09%) | $14,370,000 (-19.46%) | $17,843,000 (494.98%) |
Assets Non-Current | $11,057,000 (-8.05%) | $12,025,000 (-5.29%) | $12,697,000 (-10.54%) | $14,193,000 (8.64%) |
Goodwill & Intangible Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Shareholders Equity | $9,977,000 (318.36%) | -$4,569,000 (-159.60%) | -$1,760,000 (-279.23%) | $982,000 (123.84%) |
Property Plant & Equipment Net | $11,057,000 (-8.05%) | $12,025,000 (-5.29%) | $12,697,000 (-10.54%) | $14,193,000 (9.76%) |
Cash & Equivalents | $2,095,000 (-58.18%) | $5,010,000 (-64.76%) | $14,215,000 (-18.85%) | $17,517,000 (558.76%) |
Accumulated Other Comprehensive Income | -$1,740,000 (0.00%) | -$1,740,000 (13.30%) | -$2,007,000 (2.34%) | -$2,055,000 (0%) |
Deferred Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Investments | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Inventory | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Receivables | $83,000 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Payables | $1,382,000 (-0.14%) | $1,384,000 (-29.24%) | $1,956,000 (-5.46%) | $2,069,000 (72.52%) |
Accumulated Retained Earnings (Deficit) | -$117,539,000 (3.92%) | -$122,335,000 (-5.61%) | -$115,835,000 (-5.27%) | -$110,039,000 (-20.03%) |
Tax Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Tax Liabilities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Debt | $2,086,000 (-89.85%) | $20,561,000 (-4.55%) | $21,542,000 (-25.68%) | $28,985,000 (52.90%) |
Debt Current | $424,000 (7.07%) | $396,000 (3.66%) | $382,000 (1.87%) | $375,000 (-97.82%) |
Debt Non-Current | $1,662,000 (-91.76%) | $20,165,000 (-4.70%) | $21,160,000 (-26.04%) | $28,610,000 (1564.98%) |
Total Liabilities | $3,471,000 (-84.25%) | $22,041,000 (-23.54%) | $28,827,000 (-7.17%) | $31,054,000 (53.86%) |
Liabilities Current | $1,806,000 (1.46%) | $1,780,000 (-23.87%) | $2,338,000 (-4.34%) | $2,444,000 (-86.51%) |
Liabilities Non-Current | $1,665,000 (-91.78%) | $20,261,000 (-23.51%) | $26,489,000 (-7.41%) | $28,610,000 (1285.13%) |
SCNI Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Revenues | $658,000 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Cost of Revenue | $1,238,000 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Selling General & Administrative Expense | $2,526,000 (-43.93%) | $4,505,000 (-14.94%) | $5,296,000 (-30.54%) | $7,625,000 (61.89%) |
Research & Development Expense | $5,532,000 (6.18%) | $5,210,000 (-9.63%) | $5,765,000 (77.44%) | $3,249,000 (-77.63%) |
Operating Expenses | $8,058,000 (-16.98%) | $9,706,000 (-12.25%) | $11,061,000 (1.83%) | $10,862,000 (624.73%) |
Interest Expense | -$1,325,000 (-141.33%) | $3,206,000 (-39.11%) | $5,265,000 (0%) | $0 (0%) |
Income Tax Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | -$4,796,000 (-173.78%) | $6,500,000 (12.15%) | $5,796,000 (170.63%) | -$8,206,000 (-552.60%) |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income | -$4,796,000 (-173.78%) | $6,500,000 (12.15%) | $5,796,000 (170.63%) | -$8,206,000 (-552.60%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | -$4,796,000 (-173.78%) | $6,500,000 (12.15%) | $5,796,000 (170.63%) | -$8,206,000 (-552.60%) |
Weighted Average Shares | $3,225,472,266 (106.41%) | $1,562,627,495 (107.22%) | $754,076,407 (33.57%) | $564,575,967 (27.37%) |
Weighted Average Shares Diluted | $3,225,472,266 (106.41%) | $1,562,627,495 (107.22%) | $754,076,407 (33.57%) | $564,575,967 (27.37%) |
Earning Before Interest & Taxes (EBIT) | -$6,121,000 (-163.06%) | $9,706,000 (-12.25%) | $11,061,000 (234.79%) | -$8,206,000 (-360.12%) |
Gross Profit | -$580,000 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Operating Income | -$8,638,000 (11.00%) | -$9,706,000 (12.25%) | -$11,061,000 (-1.83%) | -$10,862,000 (-624.73%) |
SCNI Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Net Cash Flow from Investing | -$12,000 (98.12%) | -$637,000 (23.80%) | -$836,000 (-501.44%) | -$139,000 (91.70%) |
Net Cash Flow from Financing | $3,441,000 (216.85%) | $1,086,000 (-83.97%) | $6,776,000 (-68.38%) | $21,430,000 (453.55%) |
Net Cash Flow from Operations | -$6,335,000 (32.48%) | -$9,382,000 (-29.14%) | -$7,265,000 (2.17%) | -$7,426,000 (63.73%) |
Net Cash Flow / Change in Cash & Cash Equivalents | -$2,915,000 (68.33%) | -$9,205,000 (-178.77%) | -$3,302,000 (-122.87%) | $14,440,000 (181.15%) |
Net Cash Flow - Business Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Cash Flow - Investment Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Capital Expenditure | -$12,000 (98.12%) | -$637,000 (23.80%) | -$836,000 (-501.44%) | -$139,000 (91.75%) |
Issuance (Repayment) of Debt Securities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Issuance (Purchase) of Equity Shares | $3,441,000 (216.85%) | $1,086,000 (-83.97%) | $6,776,000 (-68.38%) | $21,430,000 (45637.82%) |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Effect of Exchange Rate Changes on Cash | -$9,000 (96.69%) | -$272,000 (86.24%) | -$1,977,000 (-443.83%) | $575,000 (19.00%) |
Share Based Compensation | $682,000 (-40.12%) | $1,139,000 (-28.90%) | $1,602,000 (-41.89%) | $2,757,000 (3.12%) |
Depreciation Amortization & Accretion | $1,649,000 (220.82%) | $514,000 (-8.54%) | $562,000 (19.32%) | $471,000 (-31.50%) |
SCNI Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Gross Margin | -88.10% | - | - | - |
Profit Margin | -728.90% | - | - | - |
EBITDA Margin | -679.60% | - | - | - |
Return on Average Equity (ROAE) | -253.10% (-86.79%) | -135.50% (-139.20%) | 345.70% (218.47%) | -291.80% (-2379.69%) |
Return on Average Assets (ROAA) | -33.30% (-201.52%) | 32.80% (40.17%) | 23.40% (175.97%) | -30.80% (-431.03%) |
Return on Sales (ROS) | -930.20% | - | - | - |
Return on Invested Capital (ROIC) | -29.10% (-197.32%) | 29.90% (-18.97%) | 36.90% (192.25%) | -40.00% (-539.56%) |
Dividend Yield | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) |
Price to Earnings Ratio (P/E) | - | 0.37 (-49.73%) | 0.74 (125.19%) | -2.94 (88.20%) |
Price to Sales Ratio (P/S) | 4.1 | - | - | - |
Price to Book Ratio (P/B) | 0.29 (160.34%) | -0.47 (84.91%) | -3.14 (-109.16%) | 34.3 (542.90%) |
Debt to Equity Ratio (D/E) | 0.35 (107.21%) | -4.82 (70.55%) | -16.38 (-151.79%) | 31.62 (745.50%) |
Earnings Per Share (EPS) | 0 (0%) | 16 (-60.00%) | 40 (150.00%) | -80 (-608.59%) |
Sales Per Share (SPS) | 0.82 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Free Cash Flow Per Share (FCFPS) | -7.87 (69.31%) | -25.65 (40.32%) | -42.97 (19.83%) | -53.6 (73.20%) |
Book Value Per Share (BVPS) | 12.37 (205.79%) | -11.7 (-25.28%) | -9.34 (-234.20%) | 6.96 (118.71%) |
Tangible Assets Book Value Per Share (TABVPS) | 16.68 (-62.71%) | 44.73 (-68.85%) | 143.58 (-36.74%) | 226.97 (56.58%) |
Enterprise Value Over EBIT (EV/EBIT) | 0 (0%) | 2 (100.00%) | 1 (120.00%) | -5 (-127.78%) |
Enterprise Value Over EBITDA (EV/EBITDA) | -0.65 (-142.97%) | 1.51 (19.57%) | 1.27 (122.28%) | -5.69 (-138.04%) |
Asset Turnover | 0.05 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Current Ratio | 1.32 (-56.73%) | 3.06 (-50.21%) | 6.15 (-15.82%) | 7.3 (4298.19%) |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Free Cash Flow (FCF) | -$6,347,000 (36.65%) | -$10,019,000 (-23.68%) | -$8,101,000 (-7.09%) | -$7,565,000 (65.86%) |
Enterprise Value (EV) | $2,911,271 (-81.20%) | $15,487,232 (5.19%) | $14,723,509 (-66.52%) | $43,982,103 (-23.41%) |
Earnings Before Tax (EBT) | -$4,796,000 (-173.78%) | $6,500,000 (12.15%) | $5,796,000 (170.63%) | -$8,206,000 (-552.60%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$4,472,000 (-143.76%) | $10,220,000 (-12.07%) | $11,623,000 (250.27%) | -$7,735,000 (-301.31%) |
Invested Capital | $11,633,000 (-62.77%) | $31,243,000 (-2.54%) | $32,056,000 (-21.93%) | $41,060,000 (188.27%) |
Working Capital | $585,000 (-84.05%) | $3,667,000 (-69.52%) | $12,032,000 (-21.87%) | $15,399,000 (201.86%) |
Tangible Asset Value | $13,448,000 (-23.03%) | $17,472,000 (-35.45%) | $27,067,000 (-15.51%) | $32,036,000 (99.44%) |
Market Capitalization | $2,853,271 (31.84%) | $2,164,232 (-60.86%) | $5,528,933 (-83.58%) | $33,680,542 (5.57%) |
Average Equity | $1,895,000 (139.51%) | -$4,795,750 (-386.04%) | $1,676,593 (-40.38%) | $2,812,282 (128.54%) |
Average Assets | $14,402,750 (-27.30%) | $19,810,750 (-20.18%) | $24,818,472 (-6.78%) | $26,623,246 (23.56%) |
Invested Capital Average | $21,034,500 (-35.11%) | $32,416,500 (8.11%) | $29,985,751 (46.05%) | $20,531,209 (-40.75%) |
Shares | 3,411,983,584 (134.67%) | 1,453,970,784 (94.60%) | 747,153,064 (30.33%) | 573,285,824 (26.23%) |
